What to Expect During Spravato Treatment: A Step-by-Step Guide for New Patients at Ketalink

If you or someone you care about has been living with treatment-resistant depression (TRD) or major depressive disorder (MDD) with suicidal thoughts or actions, and traditional antidepressants have not provided adequate relief, Spravato (esketamine nasal spray) may be a treatment option worth exploring. As an FDA-approved therapy administered under medical supervision, Spravato has shown the potential to help patients who have not responded to conventional approaches. Understanding the steps in Spravato treatment can help you feel more informed and prepared before your first appointment at Ketalink, serving patients in Levittown, New York, and Staten Island, New York.

This guide is designed to walk you through every phase of the treatment process so you know exactly what to expect – from your initial consultation through ongoing follow-up care.

Understanding Spravato Before Your First Visit

Spravato is a prescription nasal spray containing esketamine, a medication that works differently from most traditional antidepressants. While many conventional medications target serotonin or norepinephrine pathways, Spravato is believed to affect the glutamate system, which is the brain’s most abundant neurotransmitter. This distinct mechanism of action is one reason Spravato may help patients whose depression has not improved with other treatments.

It is important to understand that Spravato is not the same as general ketamine therapy. Spravato is an FDA-approved medication with a specific regulatory status, and it must be administered in a certified healthcare setting under the Risk Evaluation and Mitigation Strategy (REMS) program. This means every treatment session takes place in a supervised clinical environment like Ketalink, where trained medical professionals monitor your safety throughout the process.

Spravato is specifically approved for two indications:

• Treatment-resistant depression (TRD) in adults, defined as depression that has not adequately responded to at least two different antidepressant treatments
• Depressive symptoms in adults with major depressive disorder (MDD) who have active suicidal thoughts or actions

Spravato is used in conjunction with an oral antidepressant, not as a standalone therapy. Your treatment team at Ketalink will work with you to ensure the right combination of care based on your individual needs.

The Steps in Spravato Treatment: From Consultation to Follow-Up

Knowing what each phase of the treatment journey looks like can help ease uncertainty and allow you to focus on what matters most – your well-being. Below is a detailed overview of the Spravato treatment process at Ketalink.

Step 1: Initial Consultation and Evaluation

The treatment process begins with a thorough clinical evaluation. During your initial consultation at Ketalink, a qualified provider will review your medical history, current medications, previous depression treatments, and overall health status. This evaluation is essential for determining whether Spravato is an appropriate option for you.

Your provider will discuss the potential benefits and risks of Spravato, answer any questions you may have, and outline what the treatment schedule typically looks like. This is also an opportunity to talk about your treatment goals and any concerns you may be experiencing. No two patients are alike, and Ketalink takes a personalized approach to treatment planning.

Step 2: Preparing for Your Treatment Day

Once you and your provider have decided to move forward, you will receive specific instructions to prepare for your first treatment session. Common preparation guidelines may include:

• Dietary considerations: Patients are generally advised to avoid eating for at least two hours before treatment and to avoid drinking liquids for at least 30 minutes prior. This may help reduce the likelihood of nausea, which is a known side effect.
• Transportation arrangements: Because Spravato can cause sedation and other temporary effects, you will not be able to drive, operate machinery, or engage in activities requiring full alertness for the remainder of the day following your session. You must arrange for a responsible adult to drive you home.
• Medication review: Your provider may review your current medications, including nasal corticosteroids or decongestants, to ensure nothing interferes with the nasal spray’s absorption.

Arriving informed and prepared is an important part of the steps in Spravato treatment, and the team at Ketalink will make sure you have all the guidance you need ahead of time.

Step 3: Nasal Spray Administration

On the day of your treatment, you will be welcomed into a comfortable, supervised treatment room at Ketalink’s certified facility. Spravato is self-administered by the patient under the direct observation of a healthcare professional. You will not administer the medication alone or take it home.

During the administration phase:

• Your provider or a trained staff member will guide you through the process of using the nasal spray device.
• Each session typically involves two or three devices, depending on the prescribed dosage, with a five-minute rest period between each device.
• The entire administration process usually takes approximately 15 to 20 minutes.

Many patients find the process straightforward after the first session. If you have any difficulty using the device, the medical team is there to assist and ensure proper delivery of the medication.

Step 4: Post-Administration Monitoring

After you complete the nasal spray administration, you will remain at the clinic for a mandatory observation period of at least two hours. This monitoring period is a critical safety requirement of the REMS program and one of the most important steps in the Spravato treatment process.

During this time, the clinical team at Ketalink will periodically check your vital signs, including blood pressure, and monitor you for potential side effects. Common side effects that may occur during or shortly after treatment include:

• Dissociation (a feeling of being disconnected from your thoughts, surroundings, or sense of self)
• Dizziness or lightheadedness
• Nausea
• Sedation or drowsiness
• Elevated blood pressure
• Vertigo

These effects are typically temporary and tend to resolve within the two-hour monitoring window. Your provider will not clear you to leave until they are confident that it is safe for you to do so. Many patients describe the observation period as a time to rest quietly, and the team at Ketalink strives to create a calm, supportive environment throughout your visit.

Step 5: Follow-Up Care and Ongoing Treatment

Spravato treatment is not a single-session therapy. It follows a structured schedule that typically includes:

• Induction phase (weeks 1–4): Sessions are usually scheduled twice per week.
• Maintenance phase (weeks 5–8): Frequency is often reduced to once per week.
• Long-term maintenance (week 9 and beyond): Sessions may be further reduced to once every one to two weeks, as determined by your provider based on your clinical response.

Throughout this process, your provider at Ketalink will regularly assess your progress and adjust the treatment plan as needed. Spravato is always used alongside an oral antidepressant, so your overall medication regimen will be managed as part of a comprehensive approach to your mental health care.

Clinical studies have shown encouraging results, and many patients have experienced meaningful improvement in their depressive symptoms over the course of treatment. However, individual outcomes vary, and it is important to maintain realistic expectations while remaining engaged with your treatment plan.

Who Is a Candidate for Spravato Treatment?

Spravato is not intended as a first-line treatment for depression. It is specifically designed for adults who meet one of the following criteria:

• You have been diagnosed with treatment-resistant depression, meaning you have tried at least two adequate trials of different antidepressant medications without sufficient improvement.
• You have been diagnosed with major depressive disorder with active suicidal ideation or behavior, and your provider believes Spravato may be appropriate as part of your treatment plan.

During your evaluation at Ketalink, your provider will carefully assess your eligibility. Certain medical conditions, such as uncontrolled hypertension or a history of aneurysmal vascular disease, may affect whether Spravato is appropriate for you. This is why the initial consultation is such a vital component of the treatment journey.

Insurance Coverage for Spravato at Ketalink

One of the advantages of Spravato compared to some other advanced depression treatments is that it is typically covered by insurance. Ketalink accepts several major insurance providers for Spravato treatment, including Aetna, Cigna, Blue Cross Blue Shield, UnitedHealthcare, Medicare, and Medicaid. If you have coverage through one of these providers, Spravato treatment may be a more accessible option than you might expect.

For specific questions about your individual coverage, we encourage you to reach out to Ketalink directly. The team can help clarify how your plan may apply to your treatment.

Why Patients in Levittown and Staten Island Trust Ketalink

Ketalink has built a reputation for providing compassionate, medically supervised Spravato treatment in a comfortable clinical setting. Patients from Levittown, Staten Island, and surrounding areas in New York choose Ketalink because of the practice’s commitment to safety, individualized care, and a welcoming treatment environment.

Living with treatment-resistant depression can be an isolating experience, particularly when previous medications and therapies have not delivered the relief you were hoping for. Understanding the steps in Spravato treatment is an empowering first move toward exploring a new option. At Ketalink, the clinical team is dedicated to guiding you through each stage of the process with professionalism and care.

Take the Next Step Toward Treatment

If you have been struggling with treatment-resistant depression or depressive symptoms associated with MDD and suicidal thoughts, and conventional antidepressants have not been effective, Spravato treatment at Ketalink may be worth considering. As outlined in this guide, the Spravato treatment steps – from initial evaluation through ongoing maintenance – are designed to prioritize your safety while offering a structured path toward potential symptom improvement.

We encourage you to contact Ketalink to schedule a consultation and discuss whether Spravato is right for you. A qualified provider can review your treatment history, answer your questions, and help you make an informed decision about your next steps. You do not have to navigate treatment-resistant depression alone – professional support is available.